FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.